{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:29:16Z","timestamp":1791116956943,"version":"4.1.0"},"reference-count":64,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T00:00:00Z","timestamp":1267056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The appearance and rapid evolution of BSE in UK cattle in the mid 1980s, with compelling data supporting variant Creutzfeldt\u2013Jakob disease (vCJD) as its human manifestation, pose a potentially severe threat to public health. Three clinical cases and one asymptomatic case of vCJD infection have been reported in UK recipients of non\u2010leucodepleted red cell transfusions from donors subsequently diagnosed with vCJD. Plasma from both these and other donors who later developed vCJD has contributed towards plasma pools used to manufacture clotting factor concentrate. The United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO) Surveillance Study has detected asymptomatic vCJD postmortem in a haemophilic patient treated with UK plasma products including two batches of clotting factor linked to a donor who subsequently developed vCJD. Over 4000 bleeding disorder patients treated with UK plasma products are recorded on the UKHCDO National Haemophilia Database. The risk of vCJD transmission by plasma products is not known. However, public health precautions have been implemented since 2004 in all UK inherited bleeding disorder patients who received UK\u2010sourced plasma products between 1980 and 2001 to minimize the possible risk of onward vCJD transmission. We evaluate vCJD surveillance and risk management measures taken for UK inherited bleeding disorder patients, report current data and discuss resultant challenges and future directions.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2010.02220.x","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T08:04:29Z","timestamp":1267085069000},"page":"305-315","source":"Crossref","is-referenced-by-count":19,"title":["Risk reduction strategies for variant Creutzfeldt\u2013Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders"],"prefix":"10.1111","volume":"16","author":[{"given":"C. M.","family":"MILLAR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"CONNOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"DOLAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MAKRIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"WILDE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"WINTER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"IRONSIDE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"GILL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. G. H.","family":"HILL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,25]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02866081"},{"key":"e_1_2_14_3_2","first-page":"372","article-title":"Uber eine der multiplen Sklerose klinisch nahestehende Erkrankung des Zentralnervensystems (spastische Pseudosklerose) mit bemerkenswertem anatomischem Befunde","volume":"17","author":"Jakob A","year":"1921","journal-title":"Med Klin"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12075-5"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05403-4"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05128-4"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/39057"},{"key":"e_1_2_14_9_2","volume-title":"The Bovine Spongiform Encephalopathy Order","author":"Her Majesty\u2019s Stationery Office","year":"1988"},{"key":"e_1_2_14_10_2","unstructured":"The National Creutzfeldt\u2010Jakob Disease Surveillance Unit.CJD Statistics. Edinburgh UK. Available athttp:\/\/www.cjd.ed.ac.uk\/figures.htm. Accessed Feb 1 2010."},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07376.x"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60744-1"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/385197a0"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61568-3"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1442"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02706-9"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110410"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0302.970208"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114125"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90068-R"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92925-8"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09468-3"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00073.x"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64307-3"},{"key":"e_1_2_14_25_2","unstructured":"TMER.Transfusion Medicine Epidemiology Review. Available athttp:\/\/www.cjd.ed.ac.uk\/TMER\/TMER.htm. Accessed 1 Feb 2010."},{"key":"e_1_2_14_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01195.x"},{"key":"e_1_2_14_27_2","unstructured":"Department of Health.Better Blood Transfusion: Health Service Circular London UK 1998."},{"key":"e_1_2_14_28_2","unstructured":"Department of Health.Better Blood Transfusion: Health Service Circular Available athttp:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Healthservicecirculars\/DH_4004264. Accessed Feb 18 2010."},{"key":"e_1_2_14_29_2","unstructured":"Department of Health.Better Blood Trasnfusion: Health Service Circular Available athttp:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Healthservicecirculars\/DH_080613. Accessed Feb 18 2010."},{"key":"e_1_2_14_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05796.x"},{"key":"e_1_2_14_31_2","volume-title":"Position Statement on new Variant CJD and Plasma\u2010Derived Medicinal Products","author":"Committee for Proprietary Medicinal Products","year":"1998"},{"key":"e_1_2_14_32_2","unstructured":"UK Product Recall Incident.Bio Products Laboratory Hertfordshire UK 1997."},{"key":"e_1_2_14_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001003.x"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7820086.x"},{"key":"e_1_2_14_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00211.x"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03989"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.11.007"},{"key":"e_1_2_14_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00403.x"},{"key":"e_1_2_14_39_2","unstructured":"ComerP SpougeJ.Assessment of the risk of exposure to vCJD infectivity in blood and blood products. Det Norske Veritus Final Report 1999."},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_14_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_14_42_2","unstructured":"Bio Products Laboratory.Product Recall Incident Hertfordshire UK 2000."},{"key":"e_1_2_14_43_2","unstructured":"Department of Health.New variant CJD\u2010patients who have received implicated blood products 1998."},{"key":"e_1_2_14_44_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615387"},{"key":"e_1_2_14_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02719-7"},{"key":"e_1_2_14_46_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-11-2897"},{"key":"e_1_2_14_47_2","unstructured":"Det Norske Veritas Report for Department of Health. Available athttp:\/\/www.dnv.co.kr\/Binaries\/vCJD_Update_Report_tcm34\u201074414.pdf. Accessed Feb 1 2010."},{"key":"e_1_2_14_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.9.4649-4650.2002"},{"key":"e_1_2_14_49_2","unstructured":"CJDIP.Management of possible exposure to CJD through medical procedures. Available athttp:\/\/www.hpa.org.uk\/servlet\/ContentServer?c=HPAweb_C&cid=1194947314514&pagename=HPAwebFile. Accessed March 1 2004."},{"key":"e_1_2_14_50_2","volume-title":"Risk Assessment for Transmission of VCJD via Surgical Instruments: A Modelling Approach and Numerical Scenarios","author":"Department of Health","year":"2001"},{"key":"e_1_2_14_51_2","unstructured":"CJDIP.Assessment of exposure to particular batches of variant Creutzfeldt\u2010Jakob disease (vCJD) implicated plasma products. Available athttp:\/\/www.wfh.org\/2\/docs\/Safety_Supply\/vCJD_Incidents_panel.pdf. Accessed Feb 1 2010."},{"key":"e_1_2_14_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_14_53_2","unstructured":"Transfusion Medicine Epidemiology Review. Available athttp:\/\/www.cjd.ed.ac.uk\/TMER\/fate.htm. Accessed Feb 1 2010."},{"key":"e_1_2_14_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_14_55_2","first-page":"1","article-title":"New case of transfusion\u2010associated variant","volume":"16","author":"HPA","year":"2004","journal-title":"CJD"},{"key":"e_1_2_14_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_14_57_2","unstructured":"SEAC.Position statement on TSE infectivity in blood. Available athttp:\/\/www.seac.gov.uk. Accessed June 1 2006."},{"key":"e_1_2_14_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_14_59_2","unstructured":"ACDP.Transmissible spongiform encephalopathy agents: Safe working and the prevention of infection. Available athttp:\/\/www.advisorybodies.doh.gov.uk\/acdp\/tseguidance\/Index.htm. Accessed June 1 2003."},{"key":"e_1_2_14_60_2","unstructured":"ElamG.The emotional and behavioural impact of being placed at risk of Creutzfeldt\u2010Jacob Disease for public health purposes. A qualitative study exploring the views of blood donors to vCJD cases and patients surgically exposed to CJD 2010: submitted."},{"key":"e_1_2_14_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15487-1"},{"key":"e_1_2_14_62_2","unstructured":"AllisonM.Decontamination of equipment for GI endoscopy and vCJD issues\u2010some good news at last! 2008."},{"key":"e_1_2_14_63_2","unstructured":"FDA.FDA\u2019s risk assessment for variant Creutzfeldt\u2010Jakob disease (vCJD) potentially associated with the use of US licensed human plasma\u2010derived Factor VIII (pdFVIII Anti\u2010Haemophilic Factor) products and potential public health service responses.: TSEAC Meeting 2006."},{"key":"e_1_2_14_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_14_65_2","unstructured":"Department of Health. Available athttp:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_100357. Accessed Dec 1 2009."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02220.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2010.02220.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:37:09Z","timestamp":1698683829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02220.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,25]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2516.2010.02220.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02220.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,25]]}}}